A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
63actual
Sites
23
Countries
Argentina, Australia, Canada +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-24 | actual | When the study began enrolling |
| Primary completion | 2026-07-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-10 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cardiomyopathy, Hypertrophic
Intervention
- Drug: Mavacamten
Primary outcome
what the primary-completion date above is the date OFComposite of maximum left atrial volume index (LAVI) and left ventricular mass index (LVMI) at Week 48
measured At week 48
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed